Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
WHEN a deeply troubled company replaces its chief executive, it makes sense to expect the new CEO to bring a fresh take to its operations. A clean sweep, so to speak.
But if shareholders in Valeant Pharmaceuticals International envisage a vastly different approach by